Skip to main content
Clinical Trials/ChiCTR2100043154
ChiCTR2100043154RecruitingUnknown

分化型甲状腺癌术后内分泌治疗:精准线上辅助调药系统的研发

Not provided1 site in 1 country400 target enrollmentStarted: February 1, 2021Last updated:

Trial Snapshot

Phase
Unknown
Status
Recruiting
Enrollment
400
Locations
1
Primary Endpoint
促甲状腺激素

Study Overview

Brief Summary

1.我们提供一种分化型甲状腺癌患者术后终身随访评估调药辅助系统。 2.实现 APP 线上精准动态调控,辅助指导病人随访和调药,部分取代了专家面诊,有利于互联网医院和远程医疗,规范甲状腺癌患者术后的长期随访。

Study Design

Study Type
Observational

Eligibility Criteria

Ages
16 to 80 (—)
Sex
All

Inclusion Criteria

  • ①年龄:16-80 岁;
  • ②病理证实为分化型甲状腺癌;
  • ⑤体重:40-125kg

Exclusion Criteria

  • ②无法使用网络终端 APP;
  • ④伴发严重基础性疾病;
  • ⑤伴发其他甲状腺癌病理类型;

Arms & Interventions

初治期(术后≤1 年)

随访期(>1 年)

Outcomes

Primary Outcomes

促甲状腺激素

Secondary Outcomes

No secondary outcomes reported

Investigators

Study Sites (1)

Loading locations...

Similar Trials